Healthcare
Illumina, Inc.(ILMN)
Live Price
Offline$160.97
-3.15% today
1Y Change
+76.91%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $19.25B
- Revenue Growth
- -0.7%
- EPS Growth
- +171.1%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Illumina, Inc. (ILMN) is a Healthcare stock with a market cap of $19.25B and listed on NASDAQ. The stock last traded around $160.97 and up 76.9% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -0.7%, EPS growth of +171.1%, a dividend yield of 0.0%. What stands out right now is revenue -0.7%, EPS +171.1%, free cash flow +31.3% with operating margin 20.7% and ROIC 13.3%. Valuation sits in the middle of the pack at P/E 22.7 and price/sales 4.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ILMN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.7% vs +7.6% peer median
Operating Margin
Near sector median
+20.7% vs +19.4% peer median
P/E
Below sector median
22.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.7% and EPS is at +171.1%, with operating margin around 20.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -0.5% | +1.1% | +12.4% |
2026 Feb 5, 2026 | +8.9% | -10.4% | -14.3% | -6.7% |
2025 Oct 30, 2025 | +14.5% | +24.8% | +22.3% | +32.8% |
Benchmark Edge
ILMN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ILMN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ILMN Max Drawdown
-25.66%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ILMN and SPY.
Company Overview
Illumina, Inc.
NASDAQ Global Select
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
- Leadership
- Jacob Thaysen
- IPO Date
- Jul 28, 2000
- Employees
- 9.0k
- Street Address
- 5200 Illumina Way
- Mailing
- San Diego, CA, 92122
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 202 4500
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 22.7
- EV/EBITDA
- 14.8
- Price/Sales
- 4.4
- Price/Book
- 6.4
Growth
- Revenue
- -0.7%
- EPS
- +171.1%
- Free Cash Flow
- +31.3%
Profitability
- Gross Margin
- 66.6%
- Operating Margin
- 20.7%
- Net Margin
- 19.4%
- ROE
- 32.8%
- ROIC
- 13.3%
Balance Sheet
- Debt/Equity
- 0.81
- Current Ratio
- 1.75
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.